Advances in Urology

Research Article

Penile Hemodynamic Response to Phosphodiesterase Type V Inhibitors after Cavernosal Sparing Inflatable Penile Prosthesis Implantation: A Prospective Randomized Open-Blinded End-Point (PROBE) Study

Table 1

Patients’ characteristics and preoperative baseline measurements (mean ± SD, range).


	Cavernosal sparing group (n = 17)	Conventional group (n = 16)

Age (years)	47.4 ± 12.3 (30.0–69.0)	54.3 ± 11.8 (36.0–71.0)	0.1106
BMI (kg/m²)	27.2 ± 1.3 (25.0–29.7)	26.8 ± 1.1 (25.2–29.1)	0.3489
ED duration (years)	4.7 ± 2.1 (2.0–8.0)	5.1 ± 2.4 (2.0–9.0)	0.6134
Basal PSV (cm/s)	17.7 ± 5.8 (10–30)	19.1 ± 4.1 (11.3–27.7)	0.4321
PSV (cm/s) after ICI	49.9 ± 13.2 (30.9–80.0)	45.6 ± 10.9 (32.23–71.7)	0.3516
Basal EDV (cm/s)	0.1 ± 0.4 (0.0–1.4)	0 (0)	—
EDV (cm/s) after ICI	12.6 ± 4.0 (6.1–20.9)	11.8 ± 3.6 (6.1–20.1)	0.5512

BMI: body mass index; PSV: peak systolic velocity; EDV: end-diastolic velocity; ICI: intracavernosal injection.